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Streptolysin O (SLO) is a potent cytolytic toxin produced by almost all strains of group A
streptococci and is considered an important virulence factor for this organism. In this study we
investigated the effect of allicin and aqueous garlic extracts on the haemolytic activity of SLO. All
tested materials potentially inhibited the SLO haemolytic activity. Allicin neutralized SLO in a
dose- and time-dependent manner. A 15 min incubation of SLO with 35 mg allicin totally inhibited
the haemolytic activity of SLO [IC50 (concentration necessary to reach half maximum
inhibition)55.97 mg]. The inhibitory activity of an old extract of garlic was equipotent to pure allicin
(IC5056.27 mg; P,0.05). In contrast, fresh extract of garlic inhibited the SLO haemolytic activity
at lower concentrations (IC5051.59 ml; 1.9 mg allicin). The inhibitory effect of the allicin was
restored by addition of reducing agent DTT at 2 mM, suggesting that allicin likely inhibits the SLO
by binding to the cysteine residue in the binding site. These results indicate a new activity for
allicin and allicin may be a potential alternative drug against streptococcal diseases.
INTRODUCTION
Streptococcus pyogenes (group A streptococci; GAS) is a
highly versatile pathogen that causes a wide variety of
important human diseases, ranging from localized infec-
tions, such as pharyngitis, erysipelas and cellulites, to life-
threatening invasive diseases like streptococcal toxic shock
syndrome and necrotizing fasciitis (Martin & Green, 2006;
Steer et al., 2007). GAS infections are associated with non-
suppurative immune-mediated complications such as post-
streptococcal glomerulonephritis, acute rheumatic fever
and post-streptococcal reactive arthritis (Martin & Green,
2006; Steer et al., 2007). This organism has a large armoury
of virulence factors responsible for this broad range of
human diseases (Cunningham, 2008). The strains differ in
the expression of this wide range of virulence factors.
However, some virulence factors are highly conserved and
expressed by almost all strains. The potent streptococcal
cytolytic toxin streptolysin O (SLO) is among such
factors (Muller-Alouf et al., 1997; Shiseki et al., 1999).
SLO contributes to the pathogenesis of streptococcal
infections by direct toxic effects on human cell types, and
by inducting the production and release of pro-inflammat-
ory factors.
In vitro studies demonstrated that SLO kills a variety of
human cell types by disruption of the biological mem-
branes, at lethal concentrations (Alouf & Palmer, 1999),
and recently it has been reported that SLO triggers the
apoptotic death of human leukocytes, at sublethal con-
centrations (Timmer et al., 2009). Purified SLO elicits high
amounts of pro-inflammatory cytokines by immune cells
and potentiates inflammatory responses, in vitro and in
vivo (Hackett & Stevens, 1992; Shanley et al., 1996). In
parallel, isogenic SLO-deficient mutants showed a reduced
ability to elicit the production of pro-inflammatory factors
compared to parent strains (Ruiz et al., 1998). Admini-
stration of SLO in animal models produces severe
pathophysiological effects. In rabbits, intravenous admin-
istration of SLO caused blood vessel contraction, increased
capillary permeability, massive intravascular thrombosis,
dermal necrosis, cardiotoxicity and death (Alouf, 1980).
Limbago and colleagues reported that SLO-deficient GAS
was attenuated and mice infected with the stable slo mutant
exhibited a significant decrease in mortality rates compared
to mice infected with wild-type GAS (Limbago et al., 2000).
The data indicate that SLO has great potential as a drug
target for the treatment of streptococcal infections.
SLO belongs to a family of pore-forming toxins referred to
as thiol-activated toxins or recently as cholesterol-depend-
ent cytolysins (Palmer, 2001). All toxins in this family
consist of a single polypeptide chain, the length of which
ranges from 471 amino acid residues with pneumolysin
(Walker et al., 1987) to 571 amino acid residues with SLO
Abbreviations: GAS, group A streptococci; HU, haemolytic unit; IC50,
concentration necessary to reach half maximum inhibition; RBC, red
blood cell; SLO, streptolysin O.
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